Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gains from Sales and Divestitures (2016)

Viridian Therapeutics, Inc.\DE has reported Gains from Sales and Divestitures over the past 3 years, most recently at $52668.0 for Q4 2016.

  • Quarterly results put Gains from Sales and Divestitures at $52668.0 for Q4 2016, down 88.53% from a year ago — trailing twelve months through Dec 2016 was $52668.0 (down 88.53% YoY), and the annual figure for FY2016 was $52668.0, down 88.53%.
  • Gains from Sales and Divestitures for Q4 2016 was $52668.0 at Viridian Therapeutics, Inc.\DE, down from $154308.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for VRDN hit a ceiling of $459208.0 in Q4 2015 and a floor of $2352.0 in Q1 2016.
  • Median Gains from Sales and Divestitures over the past 3 years was $154308.0 (2016), compared with a mean of $200390.3.
  • Biggest five-year swings in Gains from Sales and Divestitures: skyrocketed 61.19% in 2015 and later crashed 98.15% in 2016.
  • Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures stood at $284893.0 in 2014, then skyrocketed by 61.19% to $459208.0 in 2015, then plummeted by 88.53% to $52668.0 in 2016.
  • The last three reported values for Gains from Sales and Divestitures were $52668.0 (Q4 2016), $154308.0 (Q3 2016), and $128956.0 (Q2 2016) per Business Quant data.